Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations. / Dreyling, Martin; Aurer, Igor; Cortelazzo, Sergio; Hermine, Olivier; Hess, Georg; Jerkeman, Mats; Le Gouill, Steven; Ribrag, Vincent; Trněný, Marek; Visco, Carlo; Walewski, Jan; Zaja, Francesco; Zinzani, Pier Luigi.

I: Leukemia and Lymphoma, Vol. 59, Nr. 8, 2018, s. 1814-1828.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Dreyling, M, Aurer, I, Cortelazzo, S, Hermine, O, Hess, G, Jerkeman, M, Le Gouill, S, Ribrag, V, Trněný, M, Visco, C, Walewski, J, Zaja, F & Zinzani, PL 2018, 'Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations', Leukemia and Lymphoma, vol. 59, nr. 8, s. 1814-1828. https://doi.org/10.1080/10428194.2017.1403602

APA

CBE

Dreyling M, Aurer I, Cortelazzo S, Hermine O, Hess G, Jerkeman M, Le Gouill S, Ribrag V, Trněný M, Visco C, Walewski J, Zaja F, Zinzani PL. 2018. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia and Lymphoma. 59(8):1814-1828. https://doi.org/10.1080/10428194.2017.1403602

MLA

Vancouver

Author

Dreyling, Martin ; Aurer, Igor ; Cortelazzo, Sergio ; Hermine, Olivier ; Hess, Georg ; Jerkeman, Mats ; Le Gouill, Steven ; Ribrag, Vincent ; Trněný, Marek ; Visco, Carlo ; Walewski, Jan ; Zaja, Francesco ; Zinzani, Pier Luigi. / Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations. I: Leukemia and Lymphoma. 2018 ; Vol. 59, Nr. 8. s. 1814-1828.

RIS

TY - JOUR

T1 - Treatment for patients with relapsed/refractory mantle cell lymphoma

T2 - European-based recommendations

AU - Dreyling, Martin

AU - Aurer, Igor

AU - Cortelazzo, Sergio

AU - Hermine, Olivier

AU - Hess, Georg

AU - Jerkeman, Mats

AU - Le Gouill, Steven

AU - Ribrag, Vincent

AU - Trněný, Marek

AU - Visco, Carlo

AU - Walewski, Jan

AU - Zaja, Francesco

AU - Zinzani, Pier Luigi

PY - 2018

Y1 - 2018

N2 - Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.

AB - Patients with mantle cell lymphoma (MCL) usually respond to initial combination chemotherapy, but the disease inevitably relapses and often follows an aggressive course. Here, clinical study results published since 2008 for patients with relapsed/refractory MCL were reviewed to compare available evidence for treatment guidance. Most trials identified were non-randomized, phase II studies performed at a limited number of sites, and many evaluated MCL as one of multiple non-Hodgkin lymphoma subtypes. Additional randomized, comparative trials are needed. Treatment selection generally depends on patient need, age and fitness, time of relapse, and line of therapy. Combination regimens typically produce higher response rates than single agents, and adding rituximab generally improves outcomes. The inclusion of ibrutinib, lenalidomide, temsirolimus, and bortezomib, represents an important advance for patients ineligible for, unable to tolerate, or failing high-intensity combination chemotherapy. A high need for effective treatments in relapsed/refractory MCL remains, particularly for elderly and frail patients.

KW - Chemotherapy

KW - clinical trials

KW - mantle cell lymphoma

KW - molecular targeted therapy

U2 - 10.1080/10428194.2017.1403602

DO - 10.1080/10428194.2017.1403602

M3 - Article

VL - 59

SP - 1814

EP - 1828

JO - Leukemia & Lymphoma

JF - Leukemia & Lymphoma

SN - 1029-2403

IS - 8

ER -